Theorem Clinical Research

R&D Trends

Boehringer Ingelheim, CureVac collaborate on lung cancer immunotherapy

Thursday, September 18, 2014 01:39 PM

Boehringer Ingelheim and CureVac, a clinical stage biopharmaceutical company based in Tubingen, Germany, have announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.

More... »


Sanofi, MyoKardia collaborate on genetic heart disease

Thursday, September 18, 2014 01:38 PM

Sanofi and MyoKardia, a South San Francisco-based, privately held company developing precision therapies for genetic heart disease, are collaborating to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia's pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction.

More... »


Sutro Biopharma, EMD Serono partner on antibody drug conjugates

Thursday, September 18, 2014 01:37 PM

Sutro Biopharma, a California-based biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, and EMD Serono, the biopharmaceutical division of Merck, have inked a collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells.

More... »

AstraZeneca, Eli Lilly ink agreement for AZD3293 for Alzheimer’s disease

Wednesday, September 17, 2014 02:28 PM

AstraZeneca and Eli Lilly have inked an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.

More... »

Curie-Cancer, Inventiva partners in epigenetics for cancer

Wednesday, September 17, 2014 02:25 PM

Curie-Cancer, the body responsible for Institut Curie’s industry partnership activities, and Inventiva, a French drug discovery company focusing on therapeutic approaches involving transcription factors and epigenetic targets, have launched the Epicure project, which just has received financial backing from France’s national research agency, the ANR (Agence Nationale pour la Recherche).

More... »

Denovo Biopharma acquires late-stage oncology drug from Eli Lilly

Wednesday, September 17, 2014 02:14 PM

Denovo Biopharma, a San Diego-based, privately held biotechnology company, has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data and information.

More... »

MedGenesis, Pfizer ink agreement for Parkinson's disease

Wednesday, September 17, 2014 02:13 PM

MedGenesis Therapeutix, a Canada-based, privately held biotechnology company focused on the development and precision delivery of definitive treatments for neurologic diseases, has entered into an agreement with Pfizer, granting Pfizer an exclusive, worldwide option to license its glial cell line-derived neurotrophic factor (GDNF) protein and convection enhanced delivery (CED) technology to be used in research for potential treatments for Parkinson's disease.

More... »

NIH awards $64M for the understanding of cell pathways, development of new therapies

Tuesday, September 16, 2014 09:00 AM

Building on a successful three-year pilot project, the NIH has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures (LINCS).  Discovering such cell responses will improve scientists’ understanding of cell pathways and aid in the development of new therapies for many diseases.

More... »

International Progressive MS Alliance awards $28.4M in research grants

Tuesday, September 16, 2014 08:00 AM

The International Progressive MS Alliance has awarded its first round of 22 research grants to investigators in nine countries, with the goal of removing barriers to developing treatments for progressive multiple sclerosis (MS). The alliance is a worldwide collaborative focused on finding solutions to progressive forms of multiple sclerosis that have so far eluded the scientific community.

More... »

Synergistix, MedPro Systems partner

Tuesday, September 16, 2014 07:55 AM

Synergistix, a Sunrise, Fla.-based provider of customer relationship management (CRM) solutions for life sciences, has partnered with MedPro Systems, an Arlington, N.J.-based healthcare licensing solution for pharmaceutical and device industries.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs